← Back

Jiangsu Apon Medical Technology Co Ltd Class A

Jiangsu Apon Medical Technology Co., Ltd. engages in the research and development, production, and sale of medical devices for anesthesia and analgesia, nasal airway, and chronic pain management in China. It offers pain management services, such as high-precision intelligent microcomputer infusion pumps, wireless analgesia management systems, internal heat needle therapy devices, low-frequency therapy devices, and shockwave therapy devices; and iPainfree, a wireless analgesia management system software. The company also provides nasal and upper airway management solutions, including daily nasal care, perioperative care for nasal diseases, rhinitis diagnosis and treatment, snoring diagnosis and treatment, and allergy treatment; and sleep monitoring and improvement solutions. In addition, it is involved in research and development of digital diagnostic and treatment products for neurological diseases, cognitive training, and sleep monitoring; and research, development, production, and sale of medical devices comprising brain neuromodulation and intracranial implantable electrodes. Jiangsu Apon Medical Technology Co., Ltd. was founded in 2001 and is headquartered in Nantong, China.

Price · split & dividend adjusted
News & notes moving 300753.CS
300753.CS

Aipeng Medical reports net loss of 9.88 million yuan in 2026 interim report

Aipeng Medical released its 2026 interim report, showing total operating revenue of 149 million yuan, down 6.54% year on year, and a net loss attributable to the parent company of 9.88 million yuan. Net cash flow from operating activities was negative 12.05 million yuan, the asset-liability ratio was 15.88%, gross margin was 65.50%, return on equity was negative 1.50%, and diluted earnings per share was negative 0.08 yuan. The company had 24,000 shareholders, with the top ten shareholders holding 44.14% of shares.
Jiemian·1dRead more ▾
Brain-Computer Interface

Zhejiang Issues Brain-Computer Interface Measures, Biolight Surges by 20% in Afternoon Trading

The medical device sector rebounded in afternoon trading, with Biolight hitting the 20% daily limit up. Earlier, Chaoyan Medical rose by the daily limit, Aohua Endoscopy gained over 10%, and Apon Medical, Rendu Biotechnology, Haitex, Nanwei Medical, and Lude Medical also followed the upward trend. The General Office of the Zhejiang Provincial People's Government issued several measures this morning to promote industry-academia-research collaboration in brain-computer interfaces, aiming for future industry revenue from brain-computer interfaces to exceed 5 billion yuan by 2027, and to establish a globally competitive hub for brain-computer interface technology and industry innovation by 2030.
上海证券报·14dRead more ▾
Brain-Computer Interface

A-share brain-computer interface concept stocks surge, multiple stocks hit daily limit

On the morning of July 27, A-share brain-computer interface concept stocks broke out strongly, with stocks in the sector rising collectively during the session. Chuangxin Medical hit a three-day two-board pattern, Aipeng Medical recorded a 20 percent daily limit up, Hainan Haiyao recorded a 10 percent daily limit up and hit a four-day two-board pattern, while Meihao Medical, New Journey, Yingkang Life, Xiangyu Medical, and Sanbo Brain Hospital and other concept stocks followed the rally. On the news front, a Chinese research team recently released a new type of EEG signal acquisition device, achieving for the first time globally the synchronous collection of EEG signals from over a thousand people across different regions. This breakthrough marks a key step forward in neural large model training and general brain-computer interface technology research and development. Kaiyuan Securities stated that it remains bullish on innovative drugs and their industry chain, as well as national strategic emerging industries such as AI, brain-computer interfaces, and biomanufacturing.
中国基金报·31dRead more ▾
Brain-Computer Interface

Harbin Pharmaceutical hits 5th consecutive daily limit, leading innovative drug rally; on-device AI and brain engineering sectors active

In early trading on July 16, Harbin Pharmaceutical hit its fifth consecutive daily limit, making it the stock with the longest winning streak among those still on a streak that day. The innovative drug theme remained strong, with Wanbang Pharmaceutical and Puruis rising over 10 percent. The on-device AI concept heated up, as Green Precision sealed a 20 percent daily limit, and Daoming Optics and Furong Technology also hit their daily limits. On the news front, seven on-device generative AI services completed regulatory filings, and the 2026 World Artificial Intelligence Conference is set to take place in Shanghai. The brain engineering sector saw a sudden surge during the session, with Chuangxin Medical hitting its daily limit in a straight line, and Saili Medical and Aipeng Medical following higher. The world's first implantable brain-computer interface system, NEO, saw its first prescription issued in Shanghai after receiving market approval. Total market turnover exceeded 1.4 trillion yuan, shrinking by 236.7 billion yuan compared with the same period last session, with over 3,200 stocks advancing.
上海证券报·42dRead more ▾
300753.CS

Lifecome Pharmaceuticals Clarifies It Has No Brain-Computer Interface Business or Products After Two Consecutive Limit-Up Days

Lifecome Pharmaceuticals issued a clarification announcement stating that the company has not laid out any business or products related to brain-computer interfaces. The company noted that some self-media have labeled it a brain-computer interface concept stock, but its marketed product methylphenidate hydrochloride extended-release tablets are mainly used to treat attention deficit hyperactivity disorder, and the strategic cooperation framework agreement signed with Apon Medical is aimed at jointly exploring collaborative treatment solutions involving drugs and medical devices in the attention deficit hyperactivity disorder field. This cooperation will not have an impact on the company's performance. In addition, four of the company's products have been newly included in the National Essential Medicines List 2026 edition, but product sales are affected by factors such as market access, hospital admission, professional promotion, and policies, and there is uncertainty.
央广财经·48dRead more ▾